Contrasting Inventiva (NASDAQ:IVA) & Lexaria Bioscience (NASDAQ:LEXX)

Inventiva (NASDAQ:IVA) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.

Valuation & Earnings

This table compares Inventiva and Lexaria Bioscience”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07 million	156.17	-$400.67 million	N/A	N/A
Lexaria Bioscience	$710,000.00	23.60	-$11.90 million	($0.47)	-1.44

Lexaria Bioscience has lower revenue, but higher earnings than Inventiva.

Institutional and Insider Ownership

19.1% of Inventiva shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Inventiva and Lexaria Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Lexaria Bioscience	-1,685.84%	-206.02%	-162.53%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Inventiva and Lexaria Bioscience, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1	0	6	3	3.10
Lexaria Bioscience	1	0	1	0	2.00

Inventiva currently has a consensus target price of $16.56, indicating a potential upside of 205.17%. Lexaria Bioscience has a consensus target price of $1.50, indicating a potential upside of 121.89%. Given Inventiva’s stronger consensus rating and higher probable upside, equities analysts clearly believe Inventiva is more favorable than Lexaria Bioscience.

Risk and Volatility

Inventiva has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Summary

Inventiva beats Lexaria Bioscience on 12 of the 13 factors compared between the two stocks.

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.